Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03396471 · ClinicalTrials.gov registry record · Phase 2
Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary
A Phase 2 study, sponsored by Hoosier Cancer Research Network.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT03396471 is a Phase 2 study that was terminated before completion, run by Hoosier Cancer Research Network. The registered enrollment target is 14 participants.
The verdict
NCT03396471, a Phase 2 study, was terminated before completion, sponsored by Hoosier Cancer Research Network.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
Single-arm phase 2 study to examine pembrolizumab and concurrent radiation to induce an abscopal effect in patients with previously treated carcinoma of unknown primary (CUP16-268)
Interventions
- DRUG Pembrolizumab
- RADIATION External Beam Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2023-03-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03396471
The ClinicalTrials.gov registry entry for NCT03396471 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoosier Cancer Research Network, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03396471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03396471 about?
NCT03396471 is a clinical study titled "Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary". Single-arm phase 2 study to examine pembrolizumab and concurrent radiation to induce an abscopal effect in patients with previously treated carcinoma of unknown primary (CUP16-268)
What is the current status of trial NCT03396471?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2018-02-01. Estimated completion is 2023-03-02.
What interventions are being tested in trial NCT03396471?
The interventions under investigation include: Pembrolizumab (DRUG), External Beam Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03396471?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.